Hanson Wade has made the decision to cancel this meeting. Please accept our apologies for any inconvenience or disappointment this may cause. Please register your interest here if you would like future updates on the meeting or topic.
The success of autoimmune and inflammatory models through the value chain, depends on the reliability preclinical models. Failure to optimize in vivo or in vitro models may lead to slow development and risk of clinical failure.
The inaugural Autoimmune & Inflammatory Models Summit arrives at a pivotal moment to equip your team of preclinical and translational scientists to advance their skills of model recapitulation.
Join leaders from BMS, Takeda, Seismic Therapeutics and more gain insights that will bring assurance to your model design and selection process against the 90% failure rate plaguing autoimmune and inflammatory drug development.
Harness autoimmune and inflammatory model translatability with oncology insights. Learn from Takeda’s case studies to adapt advanced in vitro platforms and predict clinical endpoints for next-generation therapies
Explore cutting-edge in vitro and humanized mouse models to redefine chronic disease targeting. Learn how AbbVie, Astellas Pharma and GentiBio leverage these advances for breakthrough validation
Navigate the upcoming FDA requirements and decipher a strategic plan towards an ex vivo future and confidence for successful IND submissions
Discover how machine learning redesigns therapeutic proteins to evade immunogenicity. Learn breakthrough strategies from Cyrus Biotechnology and Seismic Therapeutics to overcome this critical development bottleneck
Accompany companies like AbbVie and Pfizer to prioritize biologically relevant models over therapeutic convenience. Shift to a recapitulation-first approach and transform your preclinical outcomes